Novo Nordisk A/S – Share repurchase programme
November 15 2021 - 8:42AM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark,
15 November 2021
– On 5 November 2021, Novo Nordisk initiated a share repurchase
programme in accordance with Article 5 of Regulation No 596/2014 of
the European Parliament and Council of 16 April 2014 (MAR) and the
Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
"Safe Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk will
repurchase B shares for an amount up to DKK 3.7 billion in the
period from 11 November 2021 to 1 February 2022.
Since the announcement of the programme, the following
transactions have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
11 November
2021 |
105,000 |
734.79 |
77,152,736 |
12 November
2021 |
105,000 |
735.13 |
77,188,165 |
Accumulated under the programme |
210,000 |
|
154,340,901 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com. The appointed lead
manager makes its trading decisions concerning the timing of the
purchases of the shares independently of Novo Nordisk.
Transactions related to Novo Nordisk’s incentive programmes have
resulted in a net transfer from Novo Nordisk of 2,894 B shares in
the period from 8 November 2021 to 12 November 2021. The shares in
these transactions were not part of the Safe Harbour repurchase
programme.
With the transactions stated above, Novo Nordisk owns a total of
28,399,732 B shares of DKK 0.20 as treasury shares, corresponding
to 1.2% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 3 February 2021.
As of 12 November 2021, Novo Nordisk has since 3 February 2021
repurchased a total of 29,646,181 B shares at an average share
price of DKK 554.87 per B share equal to a transaction value of DKK
16,449,867,345.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 74/2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024